Table 2.
Compound | MIC50 (mg/L) (n) |
Fold change in MIC50 BCA8/H37Rv | P | |
---|---|---|---|---|
H37Rv | BCA8 | |||
Bedaquiline base | 0.04 (11) | 0.31 (10) | 7.77* | < 0.0004 |
Bedaquiline fumarate | 0.04 (6) | 0.28 (5) | 6.74* | < 0.0004 |
Clofazimine | 0.11 (7) | 0.38 (5) | 3.52* | < 0.0008 |
Thioridazine | 6.44 (6) | 10.09 (2) | 1.57* | 0.04084 |
Telithromycin | 2.28 (7) | 11.26 (5) | 4.94 | > 0.05 |
Rifampicin | 0.01 (13) | 0.02 (10) | 2.86 | > 0.05 |
Amoxicillin/clavulanic acid 2/1 | 5.73 (6) | 9.61 (4) | 1.68 | > 0.05 |
Rifapentin | ≤ 0.005 (7) | 0.01 (5) | ≥ 1.57 | > 0.05 |
Ethambutol | 1.81 (7) | 2.38 (5) | 1.31 | > 0.05 |
Moxifloxacin | 0.07 (7) | 0.08 (5) | 1.24 | > 0.05 |
Erythromycin | 5.26 (7) | ≥ 6.36 (5) | ≥ 1.21 | > 0.05 |
Clarithromycin | 0.6 (12) | 0.66 (10) | 1.09 | > 0.05 |
Rifabutin | ≤ 0.003 (6) | 0.003 (2) | ≥ 1.01 | > 0.05 |
Amikacin | 0.39 (6) | 0.36 (5) | 0.93 | > 0.05 |
Ofloxacin | 0.32 (7) | 0.29 (5) | 0.92 | > 0.05 |
Terizidone | 4.32 (6) | 3.76 (2) | 0.87 | > 0.05 |
Levofloxacin | 0.22 (13) | 0.18 (10) | 0.79 | > 0.05 |
Linezolid (batch 2) | 0.37 (7) | 0.29 (5) | 0.78 | > 0.05 |
Capreomycin | 0.61 (7) | 0.45 (5) | 0.74 | > 0.05 |
Linezolid (batch 1) | 0.47 (6) | 0.30 (5) | 0.62 | > 0.05 |
p-Aminosalicylic acid | 0.02 (7) | 0.01 (5) | 0.5 | > 0.05 |
Streptomycin | 0.33 (6) | 0.16 (2) | 0.48 | > 0.05 |
Isoniazid | 0.12 (7) | 0.05 (4) | 0.46 | > 0.05 |
Protionamide | 2.11 (5) | 0.82 (1) | 0.39 | > 0.05 |
The MIC50s for the WT (H37Rv) and an Rv0678 mutant (BCA8) are shown.
The number of times that the compound was tested is indicated in parentheses.
The MIC50 fold changes are calculated based on unrounded values.
Fold changes based on censored values become themselves censored.
The MIC50 fold changes that are statistically significant (P < 0.05) are marked with an asterisk.
Pyrazinamide was tested using the MGIT-PZA kit; both BCA8 and H37Rv were susceptible to this drug.